Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2024-05-17 Proxy Solicitation & In…
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a SEC filing labeled as a 'Schedule 14A' which is a Proxy Statement or related materials. The text specifically states it is a 'Definitive Additional Materials' supplement to a previously filed Proxy Statement, providing a notice of change of location for the 2024 Annual Meeting of Stockholders. It references the original Proxy Statement and instructs stockholders to refer to it for voting and meeting details. The document does not contain financial data, management discussion, or report content but is an update related to the proxy materials. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings fall under Proxy Solicitation & Information Statement (PSI). Since this is an additional material supplement to the Proxy Statement, it fits best under PSI rather than Regulatory Filings or Report Publication Announcement. The document length is under 5,000 characters and is a notice supplementing proxy materials, confirming PSI classification with high confidence.
2024-05-17 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 10, 2024, by Protalix BioTherapeutics, Inc. It announces the issuance of a press release with financial results for the fiscal year ended March 31, 2024, and a business update. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as Exhibit 99.1. The length of the document is 3756 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 8-K filings announcing events or press releases.
2024-05-10 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-29 English
Director's Dealing 2024
Director's Dealing
2024-04-03 English
10-K
Annual Report FY 2023
2024-03-14 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.